Literature DB >> 15802104

The gallbladder and biliary tract in cystic fibrosis.

Michael P Curry1, John E Hegarty.   

Abstract

Chronic liver disease is a major complication of cystic fibrosis. Its incidence and severity are variable, and diagnosis relies on a combination of clinical evaluation, biochemical testing, and radiologic assessment. Identifying patients who have early disease is critical, and the administration of ursodeoxycholic acid appears to be beneficial. The pathogenesis is incompletely understood, and factors that contribute to the variability in incidence and severity are unknown. Fortunately, only a small proportion of individuals progress to advanced liver disease; however, in this population, there is significant morbidity and impairment in quality of life. Liver transplantation can be performed successfully in patients with end-stage liver disease. Future treatments involve targeted gene therapy and activation of mutant forms of the cystic fibrosis transmembrane conductance regulator.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802104     DOI: 10.1007/s11894-005-0053-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  65 in total

1.  Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis.

Authors:  B Gerling; M Becker; D Staab; D Schuppan
Journal:  N Engl J Med       Date:  1997-05-29       Impact factor: 91.245

2.  Cystic fibrosis presenting with severe hemorrhage due to vitamin K malabsorption: a report of three cases.

Authors:  O L Torstenson; G B Humphrey; J R Edson; W J Warwick
Journal:  Pediatrics       Date:  1970-05       Impact factor: 7.124

3.  Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension.

Authors:  D Debray; P Lykavieris; F Gauthier; B Dousset; A Sardet; A Munck; H Laselve; O Bernard
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

4.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.

Authors:  C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

5.  Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review.

Authors:  Stuart M Williams; Robin Goodman; Anne Thomson; Kieran McHugh; David R M Lindsell
Journal:  Clin Radiol       Date:  2002-05       Impact factor: 2.350

6.  Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.

Authors:  Marie E Egan; Marilyn Pearson; Scott A Weiner; Vanathy Rajendran; Daniel Rubin; Judith Glöckner-Pagel; Susan Canny; Kai Du; Gergely L Lukacs; Michael J Caplan
Journal:  Science       Date:  2004-04-23       Impact factor: 47.728

7.  Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis.

Authors:  Cyril Flamant; Alexandra Henrion-Caude; Pierre-Yves Boëlle; François Brémont; Jacques Brouard; Bertrand Delaisi; Jean-François Duhamel; Christophe Marguet; Michel Roussey; Marie-Claude Miesch; Michèle Boulé; Richard C Strange; Annick Clement
Journal:  Pharmacogenetics       Date:  2004-05

8.  Liver cirrhosis and portal hypertension in cystic fibrosis.

Authors:  Ori Efrati; Asher Barak; Dalit Modan-Moses; Arie Augarten; Daphna Vilozni; Daniel Katznelson; Amir Szeinberg; Jacob Yahav; Yoram Bujanover
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-10       Impact factor: 2.566

9.  Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis.

Authors:  Sunil Sheth; Julie C Shea; Michele D Bishop; Sanjiv Chopra; Meredith M Regan; Emily Malmberg; Carolyn Walker; Ryan Ricci; Lap-Chee Tsui; Peter R Durie; Julian Zielenski; Steven D Freedman
Journal:  Hum Genet       Date:  2003-06-03       Impact factor: 4.132

10.  Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines.

Authors:  S A Grubman; S L Fang; A E Mulberg; R D Perrone; L C Rogers; D W Lee; D Armentano; S L Murray; H L Dorkin; S H Cheng
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

View more
  4 in total

Review 1.  Heterogeneity of the intrahepatic biliary epithelium.

Authors:  Shannon Glaser; Heather Francis; Sharon Demorrow; Gene Lesage; Giammarco Fava; Marco Marzioni; Julie Venter; Gianfranco Alpini
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

2.  The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Authors:  Sarah Poetter-Lang; Katharina Staufer; Pascal Baltzer; Dietmar Tamandl; Dina Muin; Nina Bastati; Emina Halilbasic; Jacqueline C Hodge; Michael Trauner; Lili Kazemi-Shirazi; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2018-07-27       Impact factor: 5.315

Review 3.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

4.  Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model.

Authors:  Keyan Zarei; Mallory R Stroik; Nick D Gansemer; Andrew L Thurman; Lynda S Ostedgaard; Sarah E Ernst; Ian M Thornell; Linda S Powers; Alejandro A Pezzulo; David K Meyerholz; David A Stoltz
Journal:  Lab Invest       Date:  2020-07-27       Impact factor: 5.502

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.